PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24356732-8 2013 In FL, the OR in patients treated with R-CHOP or R-CHOP-like was 85%) with 54% CR. Chromium 79-81 DNA damage inducible transcript 3 Homo sapiens 41-45 26770342-5 2015 The addition of R to standard CHOP were showed to increase the proportion of CR (RR=1.23, 95% CI=1.13-1.35, P<0.00001) and OR (RR=1.39, 95% CI=1.24-1.55, P<0.00001) in a fixed-effect model, indicating that rituximab combined with CHOP regimen is efficacy than CHOP alone. Chromium 77-79 DNA damage inducible transcript 3 Homo sapiens 30-34 27077778-10 2016 CONCLUSION: CHOPE has a trend to improve CR rate, 1-year PFS and OS compared with CHOP alone. Chromium 41-43 DNA damage inducible transcript 3 Homo sapiens 12-16 25641142-8 2015 CR rate of the 26 patients received CHOP or CHOPE regimens as the first line chemotherapy was 19.2% (5/26). Chromium 0-2 DNA damage inducible transcript 3 Homo sapiens 36-40 24356732-8 2013 In FL, the OR in patients treated with R-CHOP or R-CHOP-like was 85%) with 54% CR. Chromium 79-81 DNA damage inducible transcript 3 Homo sapiens 51-55 24356732-9 2013 With CHOP-like the OR was 59%> with 18% CR. Chromium 43-45 DNA damage inducible transcript 3 Homo sapiens 5-9 22781712-8 2012 CR rate for R-CHOP group and CHOP group was 77.01% and 71.43%, respectively. Chromium 0-2 DNA damage inducible transcript 3 Homo sapiens 12-18 22752193-5 2012 The CR rates were 93.9% for patients receiving CHOP and 92.5% for patients receiving R-CHOP. Chromium 4-6 DNA damage inducible transcript 3 Homo sapiens 47-51 22752193-5 2012 The CR rates were 93.9% for patients receiving CHOP and 92.5% for patients receiving R-CHOP. Chromium 4-6 DNA damage inducible transcript 3 Homo sapiens 87-91 22781712-8 2012 CR rate for R-CHOP group and CHOP group was 77.01% and 71.43%, respectively. Chromium 0-2 DNA damage inducible transcript 3 Homo sapiens 14-18 19309523-7 2009 However for overall response (CR+Partial response, PR), R-CHOP was superior, with odds ratios of 5.45 (95% CI: 2.51 - 11.83) and 5.54 (95% CI: 2.69 - 11.40), for the first and second analyses, respectively. Chromium 30-32 DNA damage inducible transcript 3 Homo sapiens 58-62 19593797-12 2009 CONCLUSIONS: R-CHOP + bortezomib was an effective regimen and produced an 84% CR rate. Chromium 78-80 DNA damage inducible transcript 3 Homo sapiens 15-19 22175899-18 2011 Treatment with R-CHOP usually leads to CR. Chromium 39-41 DNA damage inducible transcript 3 Homo sapiens 17-21 18718094-5 2008 The results showed that the CR rate in R-CHOP group was higher than that in CHOP group (69.7% vs 47.2%, p = 0.049); especially in patients of male, Ann Arbor III - IV and IPI 3 - 5 (p = 0.017, p = 0.005 and p = 0.000). Chromium 28-30 DNA damage inducible transcript 3 Homo sapiens 41-45 18718094-5 2008 The results showed that the CR rate in R-CHOP group was higher than that in CHOP group (69.7% vs 47.2%, p = 0.049); especially in patients of male, Ann Arbor III - IV and IPI 3 - 5 (p = 0.017, p = 0.005 and p = 0.000). Chromium 28-30 DNA damage inducible transcript 3 Homo sapiens 76-80 15585627-9 2004 The CR rates in patients at CS III and CS IV treated by CHOP, 55.2% (14 of 26) and 16.0% (5 of 28) for the low and high plasma GSTP1-1 groups, respectively, were significantly different (P < 0.01). Chromium 4-6 DNA damage inducible transcript 3 Homo sapiens 56-60 10580566-3 1999 The CR rate was 47.0% for CHOP, 76.3% for COP-BLAM, 67.9% for COP-BLAM III, and 74.4% for THP-COPBLM therapy (p = 0.013). Chromium 4-6 DNA damage inducible transcript 3 Homo sapiens 26-30 15301718-11 2004 In CHOP+HD-MTX group, CR rate was 83%, PR rate was 16%. Chromium 22-24 DNA damage inducible transcript 3 Homo sapiens 3-7 12270058-9 2002 Rituximab thus led to CR in 10/14 patients [71% (95% CI: 42-92%)] who had merely achieved partial remission (PR) with CHOP. Chromium 22-24 DNA damage inducible transcript 3 Homo sapiens 118-122 6185212-4 1983 CR rate for 65 patients with large cell lymphoma treated with CHOP-BCG was 68% compared to 48% in 61 patients treated with CHOP-bleomycin (P = 0.02) (two-tailed test) or 44% for 45 patients treated with COP-bleomycin (P = 0.02). Chromium 0-2 DNA damage inducible transcript 3 Homo sapiens 62-66 17977418-2 1994 In our series of patients and therapeutical conditions the CHOP protocol proves somewhat superior to the second and third generation protocols: persentige of complete remission (CR) was high (64%), mean duration of CR was among longes (12 months), while neither cases of relapse during the monitoring of patients were noted not toxic effects of therapy. Chromium 178-180 DNA damage inducible transcript 3 Homo sapiens 59-63 17977418-2 1994 In our series of patients and therapeutical conditions the CHOP protocol proves somewhat superior to the second and third generation protocols: persentige of complete remission (CR) was high (64%), mean duration of CR was among longes (12 months), while neither cases of relapse during the monitoring of patients were noted not toxic effects of therapy. Chromium 215-217 DNA damage inducible transcript 3 Homo sapiens 59-63 10920899-5 1997 In 10 untreated patients CR was observed in 7; The CHOP group gave an overall response rate of 65.4%(17/26). Chromium 25-27 DNA damage inducible transcript 3 Homo sapiens 51-55 1699008-5 1990 The four patients with recurrent disease after CHOP therapy exhibited a CR ratio of 50% indicating that therapy is effective in recurrent cases. Chromium 72-74 DNA damage inducible transcript 3 Homo sapiens 47-51 2681883-4 1989 As to 14 patients treated with CHOP regimen, CR rate was 87% and RFS curve trend toward plateau at 67% after 2 years and 3 months from the initiation of chemotherapy. Chromium 45-47 DNA damage inducible transcript 3 Homo sapiens 31-35 2681883-6 1989 The CHOP regimen was effective in the treatment of III-IV Hodgkin"s disease but an alternative multidrug chemotherapy with ADM, CPM, VCR, BLM, etoposide and procarbazine is recommended for achieving a higher CR rate and a better RFS. Chromium 134-136 DNA damage inducible transcript 3 Homo sapiens 4-8 6185212-5 1983 CR duration for both CHOP-based regimens was similar and superior to that produced by COP-bleomycin (P = 0.03). Chromium 0-2 DNA damage inducible transcript 3 Homo sapiens 21-25 84706-3 1979 Confirmed rates of CR for 443 evaluable patients were 59% for 286 patients receiving the CHOP regimens and 59% for 157 patients receiving COP-Bleo. Chromium 19-21 DNA damage inducible transcript 3 Homo sapiens 89-93 84706-6 1979 For patients with diffuse lymphomas the CR rate was higher with the CHOP programs (58%) than with COP-Bleo (44%) (p = 0.10). Chromium 40-42 DNA damage inducible transcript 3 Homo sapiens 68-72 29477024-4 2018 NLR >=6 was associated with lower CR rate to R-CHOP (46% vs. 74%; p = 0.02) and there was a trend towards significance in multivariate regression analyses (OR 0.36, 95% CI 0.11-1.00; p = 0.05). Chromium 37-39 DNA damage inducible transcript 3 Homo sapiens 50-54 30547695-5 2019 CR rates for PTCL and DLBCL patients were 46% and 49%, respectively, similar with reported CR rates with CHOP-like chemotherapy (p = .6). Chromium 91-93 DNA damage inducible transcript 3 Homo sapiens 105-109